Is Crowdfunding the Solution to Growing Psychedelic-Assisted Therapy?
Crowdfunding Psychedelic Research
The medical benefits of psychedelic drugs have been proven repeatedly, so why hasn’t there been more funding funneled into its research and development? The short answer is that big pharmaceutical companies can’t patent and reap profit from them.
Of course, there is also the stigma behind illegal drugs and their scheduling, but according to scientists leading the charge in research behind drugs like MDMA, LSD and Psilocybin, funding is the biggest hindrance.
This has led research groups like the Beckley Foundation and the Multidisciplinary Association for Psychedelic Studies, or MAPS, to look to crowdfunding campaigns for money. These groups have found clinical success in the past and haven’t had a lot of trouble getting government permission to test scheduled drugs, they just need resources.
That’s why there’s Fund a mental (health revolution). It’s a crowdsourcing campaign designed to garner money to donate to these organizations that have had success with treating mental health issues like PTSD, addiction and end-of-life anxiety, by using psychedelic drugs paired with intensive psychotherapy. The campaign was started by Rodrigo Niño, a man who, after taking the DMT-containing Ayahuasca, rid himself of severe anxiety upon discovering he had cancer.
Forbidden Fruits of Psychedelics
The Multidisciplinary Association for Psychedelic Studies researches psychedelic drugs ranging from LSD, to Ibogaine and Ayahuasca. But their successful research treating PTSD with MDMA has gained them the most attention in scientific communities and the media. Repeated successful studies by MAPS has led them to try to expedite FDA approval by applying for breakthrough therapy status, potentially making MDMA available with a prescription by 2021.
Their success was described in a New York Times article saying, “patients reported a 56 percent decrease of severity of symptoms on average, one study found. By the end of the study, two-thirds no longer met the criteria for having PTSD.”
MAPS wants you to know that MDMA is not the same as “Ecstasy” or “molly,” and that their trials are carefully monitored in a controlled environment, while paired with intense psychotherapy.
There is clearly a cohesive community in this realm as MAPS works together often with The Beckley Foundation as well as NYU’s School of Medicine and other notable researchers like David Nutt. They have even started a week of talks and workshops called the Psychedelic Science Conference held in Oakland, joining members of the community from all over the world.
The Beckley Foundation
When Amanda Fielding discovered LSD in the 60s, she instantly understood the potential that the drug had for consciousness expansion, especially when it came to the creative process. Since then, the drug has been scheduled and vilified in the mainstream, but she knew that the best way to change that perception was to prove its utility through science.
One of the things that her foundation focuses on that is gaining in popularity and intrigue is micro-dosing. With the rise of nootropics and “biohacking,” many people, notably in the tech world, are looking for ways to increase cognitive function and mental performance, by way of psychotropic drugs and supplements. Micro-dosing involves taking a significantly diluted or small amount of a hallucinogenic drug, like LSD or Psilocybin, that does not make you trip. The effects can lead to higher levels of creativity, positive mood and an alert, awakened state. There is no scientific evidence of this, yet. Fielding hopes to change that.
We know that psychedelics can lead to awakened states of consciousness and have the power to heal. With the stigma slowly starting to lift in the mainstream, it seems that a push from the public could be what is needed to clear the final hurdles. Since the failure of the war on drugs, medical marijuana is rapidly being legalized or decriminalized in many states with numerous benefits clinically and fiscally. We could be on the verge of a revolution in decriminalization and sweeping changes in drug policy.
Bicycle Day 2022 – 79 Years Since Albert Hofmann's LSD Discovery
Eight years before Albert Hofmann first synthesized LSD in 1938, Harry J. Anslinger was appointed the founding commissioner of the U.S. Treasury’s Federal Bureau of Narcotics. While both men were of Swiss descent and their life’s work centered around public drug use, their paths couldn’t have been more divergent. And now for this year’s Bicycle Day, as the tides of drug policy are shifting quicker than ever, their stories are increasingly relevant.
While most consider the United States’ war on drugs to have started with the Nixon or Reagan administrations, author Johann Hari in his book Chasing the Scream: The First and Last Days of the War on Drugs, urges our reconsideration of the country’s infamously failed attempt at drug prohibition to an earlier date.
Hari argues that based on racism, classism, and other prejudices, Anslinger was largely responsible for creating a zeitgeist of public misconception about nearly every drug, without regard to therapeutic applications or larger societal implications.
And though Anslinger’s tenure ended just before the criminalization of LSD, it was the foundation he set in place that widely villainized the chemical for decades.
But with the recent relaxation around psychedelic substances and the recognition of their potential as powerful healing modalities, Hofmann’s radical discovery may finally be realized for what he envisioned it could be.